Prinivil Articles
Antihypertensive Sales "Set To Decline"
1 August 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
Zeneca Pharma Opens New Granulation Unit
10 July 1997
Ramipril Slows Kidney Disease, REIN Study Shows
3 July 1997
Richter Gedeon: Independent And Profitable
5 May 1997
US Launch For Novartis' Valsartan
10 March 1997
FDA Year-End Approval Spate As Expected
6 January 1997
Zeneca Files For 311C90 Approval
2 December 1996
Zeneca Shows Its Strength At Nine Months Stage
4 November 1996
Strong Fundamentals On Show At Zeneca
19 August 1996
"Excellent" 1st Half For Zeneca But Share Price Falls
12 August 1996
US Drug Majors See 2nd-Half Double-Digit Growth
29 July 1996
Japanese Price Cuts: The Myths And Realities
15 April 1996
Independent Position To Be Maintained At Zeneca
18 March 1996
Zeneca Reveals Strong '95 Profits
11 March 1996
GW Licenses Migraine Drug To Zeneca
19 February 1996
World Markets: Cancer, Cardiovascular, Menopause
19 February 1996
FDA Panel Verdict On Calcium Blockers
5 February 1996
Zeneca Takes Charge, But Still At Forecasts' Top-End
29 January 1996
Zeneca / Bayer: Sular agreement
22 January 1996
UK Prescription Medicine Code Of Practice Review
4 December 1995
Lisinopril Cleared Post-MI In USA
4 December 1995
US FTC "Must Monitor Company/PBM Deals"
20 November 1995
Merck & Co / Zeneca have "approvable" lisinopril products
23 October 1995
Zeneca's ACE Inhibitor Zestril Licensed For AMI
14 August 1995
Zeneca's Pharma Sales Go Over L1 Billion
7 August 1995
Zeneca's Zestril approved in Japan for heart failure
10 July 1995
Good Performance Forecast For Euro Drugmakers
26 June 1995
Zeneca's Zestril approved in France
5 June 1995
Disease ManagementThe Way Forward
15 May 1995
Merck's Cozaar Approved In The USA
24 April 1995
US Difficulties For Zeneca In 1994
6 March 1995
Zeneca Seeks Post-MI Indication For Zestril
9 January 1995
Zeneca's Sales Advance 8% In The First Nine Months Of 1994
31 October 1994
Losartan Gains First Approval In Sweden
10 October 1994
Who's Knocking On The Door Of Boots?
3 October 1994
Zestril Launched In China
22 August 1994
Zeneca Praises 1st Half Underlying Growth
8 August 1994
GENERIC COs ABUSE PATENTS SAYS PMAC
11 July 1994
ZENECA GETS ANALYST UPGRADING
11 July 1994
ITALIAN POLICE SEIZE ILLICIT DRUGS MONEY
27 June 1994
ANTIHYPERTENSIVES FAIL TROUGH-PEAK CRITERIA
20 June 1994
ZESTRIL EFFECTIVE IN MI
6 June 1994
MERCK & CO POSTS 10% PR0FIT RISE
25 April 1994
ZENECA'S PIPELINE ON TARGET AS TENORMIN SLIPS
14 March 1994
"SUCCESS" IN FIRST YEAR FOR ZENECA
7 March 1994
BETTER SECOND HALF FOR ZENECA
31 January 1994
ZENECA DEVELOPING CHINESE BUSINESS
24 January 1994
ACCUPRIL APPROVED FOR CHF INDICATION
15 November 1993
FURTHER RESULTS FROM THE GISSI-3 STUDY
15 November 1993
FIRST RESULTS FROM GISSI-3 STUDY
8 November 1993
LISINOPRIL LICENSE EXTENDED IN UK
20 September 1993
ADAPTING TO A CHANGING DRUG IND ENVIRONMENT
20 September 1993
ZESTRIL APPROVED FOR GP INITIATION
6 September 1993
US DRUGSTORE AUDIT DATA FOR JULY
6 September 1993
ZENECA SURPRISES WITH STRONG PHARMA GROWTH
9 August 1993
ZENECA MAKES GOOD ADVANCES IN 1st HALF
2 August 1993
FAVORABLE TOXICITY FOR TANAPRIL
5 July 1993
ZESTRIL APPROVED FOR CHF IN USA
21 June 1993
RESTRICTIONS ON ZENECA LIFTED
21 June 1993
LISINOPRIL META-ANALYSIS
14 June 1993
DIPRIVAN INDICATION EXTENDED IN USA
15 March 1993
TENORMIN DRAGS DOWN ZENECA AS IT DEMERGES
8 March 1993
FDA PANEL ADVISES ON ACE INHIBITOR DRUGS
1 March 1993
ICI LAUNCHES ZESOTERIC IN SPAIN
1 March 1993
EUROPE STOCK COMMENT
8 February 1993
LISINOPRIL BETTER THAN ENALAPRIL?
8 February 1993
NEW HEART FAILURE STUDY
25 January 1993
ZENECA'S PROMISING R&D PIPELINE PRESENTED
14 December 1992
ICI AT "BREAKING POINT" WITH DEMERGER
14 December 1992
LICENSING DEAL FOR LISINOPRIL PRODUCTS
22 June 1992
META-ANALYSIS SHOWS LISINOPRIL HELPS IN LVH
22 June 1992
GOOD SALES GROWTH FOR MAJOR US COS IN 1st QTR
27 April 1992
POST-ELECTION OUTLOOK FOR UK HEALTH SECTOR
20 April 1992
TEN YEARS OF ACE INHIBITION
23 March 1992
MORE ICI PUERTO RICO INVESTMENT
16 March 1992
MS&D GREECE SALES RISE 19%
3 February 1992
GOOD 1991 RESULTS FOR MERCK AND FOREST LABS
3 February 1992
ICI, UPJOHN TO DROP SUMITOMO JVs
20 January 1992
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
